Author

NAZRIN YUSUFOVA

Observed names: N Yusufova, N. Yusufova, Nazrin Yusufova

Institution: AstraZeneca (United States)

Observed institution: AstraZeneca (United States)

OpenAlex ID: A5116047541

Evaluation of a disease-state education program in asthma: Application of the Knowledge-to-Action Framework

2025 · Nazrin Yusufova, Ileen A. Gilbert, et al. · Allergy and Asthma Proceedings · 1

Beta2-agonist and anti-inflammatory combination therapy for asthma rescue: a paradigm shift in asthma care

2026 · Neil Skolnik, Jessica Stieritz, et al. · Frontiers in Medicine

B22-23 Albuterol-budesonide Rescue Enhances Improvements in Control Compared With Albuterol Rescue for Patients With Mild Asthma

2026 · A Papi, B E Chipps, et al. · American Journal of Respiratory and Critical Care Medicine

D22-13 Sex Disparities in Physician Assessment of Asthma Control: Evidence for Asthma Impairment and Risk Questionnaire-based Treatment Decisions

2026 · J Reibman, J Most, et al. · American Journal of Respiratory and Critical Care Medicine

B22-18 Impact of As-needed Albuterol-budesonide on Symptoms in Moderate-to-severe Asthma: A Mandala Post-Hoc Analysis

2026 · R A Panettieri, B E Chipps, et al. · American Journal of Respiratory and Critical Care Medicine

Efficacy of Albuterol-budesonide vs Albuterol in Mild Asthma on Disease Control Over Time

2026 · Kevin Murphy, Alberto Papi, et al. · Journal of Allergy and Clinical Immunology

Efficacy Of As-needed Albuterol‒Budesonide Versus Albuterol In Participants With Mild Asthma Not On Maintenance Therapy: BATURA Post-hoc Analysis

2026 · Monica Kraft, Reynold Panettieri, et al. · Journal of Allergy and Clinical Immunology

Use of as-needed Albuterol–budesonide Is Associated with a Higher Probability of Symptom-free Nights Than as-needed Albuterol in Moderate-to-Severe Asthma

2026 · Bradley Chipps, Richard Beasley, et al. · Journal of Allergy and Clinical Immunology

Albuterol–budesonide Reduces Exacerbations in Uncontrolled Mild Asthma With or Without Exacerbation History-based Risk

2025 · B. Chipps, R. Beasley, et al. · Annals of Allergy Asthma & Immunology

As-needed Albuterol-budesonide Vs As-needed Albuterol Decreases Severe Exacerbation Risk and Improves Asthma Control at 16 Weeks in Mild Asthma: Batura Post-hoc Analyses

2025 · REYNOLD A PANETTIERI, BRADLEY E CHIPPS, et al. · CHEST Journal

Asthma Control in Participants With Mild Asthma Enrolled in the Batura Clinical Trial: Impairment and Risk Profiles at Randomization

2025 · MIGUEL J LANZ, BRADLEY E CHIPPS, et al. · CHEST Journal

Corticosteroid-associated Systemic Adverse Events in Patients on Background Inhaled Corticosteroid Maintenance Therapy and Taking Albuterol-Budesonide Versus Albuterol as Rescue: Post-hoc Analysis of MANDALA

2025 · M.J. Lanz, O. Motawakel, et al. · American Journal of Respiratory and Critical Care Medicine

Works count: 12

Citation count: 1

H-index: 1

I10-index: